Gilead Sciences Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
October 28, 2020 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.11, $0.16 better than the analyst estimate of $1.95. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.39 billion. Veklury (remdesivir) revenues were $873 million for the third quarter.
The recent acquisition of Immunomedics has effectively transformed Gileads growth story. Building on the foundation of our strong core business, which proved its durability once again this quarter, we have now significant opportunity to drive additional growth at an accelerated pace, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Trodelvy, an approved medicine with... More
